Zobrazeno 1 - 10
of 2 070
pro vyhledávání: ''
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Sebastian F. Schoppmann, Emmanuella Guenova, Gerd Jomrich, Matthias Preusser, Robin Ristl, Dariga Ramazanova, Aysegül Ilhan-Mutlu, Richard Grose, Christina Fassnacht, Dagmar Kollmann, Yi-Chien Tsai
Publikováno v:
European Journal of Surgical Oncology. 48:383-390
The effects of cytotoxic chemotherapy on the expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) in cancer cells and peritumoral cells are unclear. The aim of this study was to investigate the impact of neoadjuvant chemotherapy on PD-
Autor:
Atanas Ignatov, Piotr Czapiewski, Thomas Kalinski, Willi Pieper, Norbert Nass, Johannes Haybaeck
Publikováno v:
Cancer Biomarkers. 32:161-173
BACKGROUND: Neuronatin (NNAT) determined by immunohistochemistry is a negative prognostic biomarker for breast cancer, independent of the major clinicopathological markers. OBJECTIVE: Here, we investigated whether NNAT is also a predictive biomarker
Autor:
Junichi Ikeda, Takashi Yoshida, Chisato Ohe, Hidefumi Kinoshita, Koji Tsuta, Haruyuki Ohsugi, Motohiko Sugi
Publikováno v:
Anticancer Research. 41:4577-4586
Background/aim Expression of programmed death ligand-1 (PD-L1) is associated with poor prognosis in renal cell carcinoma (RCC). Although a new antibody clone for immunohistochemical assay, 73-10, has shown greater sensitivity than other assays (28-8,
Autor:
Stephen Ellis, Louise Lim, Amanda Johnston, Chiung-Fang Shiu, Paula Wells, Xiaoxing Feng, Melissa Phillips, Pui Ying Chan, Sukaina Rashid, Jeremy P.C. Steele, Michael Sheaff, Marianne Grantham, John Conibear, Peter W. Szlosarek, Akhila Wimalasingham, John S. Bomalaski, Peter E Hall, Chih-Ling Kuo
Publikováno v:
Cancer Medicine, Vol 10, Iss 19, Pp 6642-6652 (2021)
Cancer Medicine
Cancer Medicine
Introduction We evaluated the arginine‐depleting enzyme pegargiminase (ADI‐PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1‐deficient non‐squamous non‐small cell lung cancer (NSCLC) via a phase 1 dose‐expansion tr
Autor:
Abdurrahman Aldiab, Ammar C. Al-Rikabi, Khalid Alsaleh, Nashwa Abd El-Aziz, Tareq Salah, Sufia Husain, Maria Arafah
Publikováno v:
Clinical Breast Cancer. 21:e362-e367
Progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) significantly influence disease prognosis and therapeutic response in patients with breast cancer. Neoadjuvant chemotherapy (NACT) can change the
Autor:
Tanya B. Dorff, Christina Phuong, Siamak Daneshmand, Leslie K. Ballas, Susan M McCarthy, Kent W. Mouw, Croix C. Fossum, Yin Xiong, Manju Aron, Anthony Magliocco, Zarko Manojlovic, Sumeet Bhanvadia
Publikováno v:
Anticancer Research. 41:3851-3857
BACKGROUND/AIM Muscle invasive bladder cancer (MIBC) is an aggressive disease with high rates of local recurrence following radical cystectomy (RC). Currently, there are no clinically validated biomarkers to predict local only recurrence (LOR) and gu
Publikováno v:
Cancer Medicine, Vol 10, Iss 14, Pp 4743-4751 (2021)
Cancer Medicine
Cancer Medicine
Objective Neuroendocrine cervical cancer (NECC) is a rare cervical cancer with high aggressivity that causes poor prognosis even in the early stage. Given other neuroendocrine carcinomas and other types of cervical cancer have been proved to have exp
Autor:
Marko Bergovec, Andreas Leithner, Mark Goda, Maria Anna Smolle, Laurin Herbsthofer, Susanne Scheipl, Amin El-Heliebi, Martina Tomberger, Christopher Rossmann, Martin Pichler, Pablo López-García, Bernadette Liegl-Atzwanger, Barbara Prietl, Barbara Granegger, Armin Gerger, Joanna Szkandera, Jakob M. Riedl, Iva Brcic
Publikováno v:
Br J Cancer
BACKGROUND: Soft tissue sarcomas (STS) are generally considered non-immunogenic, although specific subtypes respond to immunotherapy. Antitumour response within the tumour microenvironment relies on a balance between inhibitory and activating signals
Publikováno v:
Cancer Immunology, Immunotherapy. 71:25-38
Tumor-infiltrating CD8 cells and expression of programmed cell death ligand 1 (PD-L1) are immune checkpoint markers in patients with hepatocellular carcinoma (HCC). We aimed to determine the ability of preoperative gadoxetic acid-enhanced magnetic re